中文｜English
ISSN 1001-5256 (Print)
ISSN 2097-3497 (Online)
CN 22-1108/R
Volume 41 Issue 12
Dec.  2025
Turn off MathJax
Article Contents
Article Navigation >  Journal of Clinical Hepatology  > 2025  >  41(12): 2562-2571

Disease burden analysis of hepatoblastoma in China based on the 2021 global burden of disease database

DOI: 10.12449/JCH251218
  • 1.

    Department of General Surgery，The Second Hospital of Lanzhou University，The Second Clinical Medical School of Lanzhou University，Lanzhou 730000，China

  • 2.

    Gansu Provincial Key Laboratory of Environmental Oncology，Lanzhou 730000，China

  • 3.

    Department of Hematology，The Second Hospital of Shanxi Medical University，Taiyuan 030000，China

Research funding:

National Natural Science Foundation of China (82260555);

Gansu Provincial Major Science and Technology Projects (22ZD6FA021-4)

More Information
  • Corresponding author: ZHOU Wence， zhouwc129@163.com （ORCID： 0000-0002-0529-7777）
  • Received Date: 2025-07-02
  • Accepted Date: 2025-08-14
  • Published Date: 2025-12-25
    Abstract
  •   Objective  To investigate the spatiotemporal changes of the disease burden of hepatoblastoma （HB） in China from 1990 to 2021， to predict future trends， and to analyze the correlation between disease burden and socioeconomic factors.  Methods  The 2021 Global Burden of Disease database was used to obtain the disease burden data of HB in China in 1990 — 2021， including the absolute numbers and age-standardized rates of incidence， mortality， and disability-adjusted life years （DALY）. The Joinpoint regression model was used to analyze the temporal trends in disease burden， and an age-period-cohort （APC） model was constructed to investigate the contribution of three main factors driving the changes in disease burden. Health inequality analysis was used to investigate the correlation between disease burden and the socio-demographic index （SDI）， and Autoregressive Integrated Moving Average and Bayesian Age-Period-Cohort models were established to predict the future disease burden of HB.  Results  There was a significant reduction in the disease burden of HB in China from 1990 to 2021， and the numbers of incidence， mortality， and DALY were reduced by 75.62% （42.69% globally）， 86.26% （49.96% globally）， and 86.32% （49.93% globally）， respectively. The age-standardized incidence rate （ASIR）， age-standardized mortality rate （ASMR）， and age-standardized DALY rate ［AS（DALY）R］ of the disease were reduced by 3.90%， 4.44%， and 5.93%， respectively， with greater reductions than the global levels （2.03%， 2.19%， and 2.73%， respectively）. The APC model showed that age effect （25.17%） and epidemiological trend （87.46%） were the main driving factors， and nonlinear correlation was observed between SDI and disease burden. Predictive models showed that ASIR would continue to decline after 2021， while ASMR and AS（DALY）R would remain stable.  Conclusion  There was a tendency of reduction in the disease burden of HB in China in 1990 — 2021， with age effect and epidemiological trend as the main driving factors， and the SDI correlation analysis shows that it is needed to focus on the optimization of prevention and control in regions with medium to high levels of development. Prediction results indicate the sustained effectiveness of current prevention and control strategies， but the risk of diseases in specific age groups should be closely monitored.

     

    • FullText(HTML)
  • loading
    • References(28)
  • [1]
    SHARMA D, SUBBARAO G, SAXENA R. Hepatoblastoma[J]. Semin Diagn Pathol, 2017, 34( 2): 192- 200. DOI: 10.1053/j.semdp.2016.12.015.
    [2]
    GUO CN, LIU ZQ, ZHANG X, et al. Global, regional, and national epidemiology of hepatoblastoma in children from 1990 to 2021: A trend analysis[J]. Hepatol Int, 2025, 19( 1): 156- 165. DOI: 10.1007/s12072-024-10750-x.
    [3]
    TANG MJ, MA XL, HE XL, et al. A multicenter prospective study on the management of hepatoblastoma in children: A report from the Chinese Children's Cancer Group[J]. World J Pediatr, 2024, 20( 6): 590- 601. DOI: 10.1007/s12519-023-00750-6.
    [4]
    GBD 2021 Causes of Death Collaborators. Global burden of 288 causes of death and life expectancy decomposition in 204 countries and territories and 811 subnational locations, 1990-2021: A systematic analysis for the Global Burden of Disease Study 2021[J]. Lancet, 2024, 403( 10440): 2100- 2132. DOI: 10.1016/S0140-6736(24)00367-2.
    [5]
    ZENG SQ. Joinpoint regression model and its application in epidemic trend analysis of infectious diseases[J]. Chin J Health Stat, 2019, 36( 5): 787- 791.

    曾四清. Joinpoint回归模型及其在传染病流行趋势分析中的应用[J]. 中国卫生统计, 2019, 36( 5): 787- 791.
    [6]
    ROSENBERG PS, MIRANDA-FILHO A, WHITEMAN DC. Comparative age-period-cohort analysis[J]. BMC Med Res Methodol, 2023, 23( 1): 238. DOI: 10.1186/s12874-023-02039-8.
    [7]
    KNOLL M, FURKEL J, DEBUS J, et al. An R package for an integrated evaluation of statistical approaches to cancer incidence projection[J]. BMC Med Res Methodol, 2020, 20( 1): 257. DOI: 10.1186/s12874-020-01133-5.
    [8]
    LU YF, WANG BB, WANG Y. Progress in nursing research for children with hepatoblastoma after liver transplantation[J/OL]. Chin J Transplatation Electron Ed, 2024, 18( 6): 412- 416. DOI: 10.3877/cma.j.issn.1674-3903.2024.06.011.

    陆晔峰, 王贝贝, 王艳. 肝母细胞瘤患儿移植护理研究进展[J/OL]. 中华移植杂志(电子版), 2024, 18( 6): 412- 416. DOI: 10.3877/cma.j.issn.1674-3903.2024.06.011.
    [9]
    FENG JC, POLYCHRONIDIS G, HEGER U, et al. Incidence trends and survival prediction of hepatoblastoma in children: A population-based study[J]. Cancer Commun, 2019, 39( 1): 62. DOI: 10.1186/s40880-019-0411-7.
    [10]
    ZHU LR, ZHENG WQ, GAO Q, et al. Epigenetics and genetics of hepatoblastoma: Linkage and treatment[J]. Front Genet, 2022, 13: 1070971. DOI: 10.3389/fgene.2022.1070971.
    [11]
    CAO YB, WU SR, TANG HW. An update on diagnosis and treatment of hepatoblastoma[J]. Biosci Trends, 2024, 17( 6): 445- 457. DOI: 10.5582/bst.2023.01311.
    [12]
    Compilation and Examination Expert Group for Guidelines for the diagnosis and treatment of hepatoblastoma(2019). Guidelines for the diagnosis and treatment of hepatoblastoma(2019)[J]. J Clin Hepatol, 2019, 35( 11): 2431- 2434. DOI: 10.3969/j.issn.1001-5256.2019.11.008.

    儿童肝母细胞瘤诊疗规范(2019年版)编写审定专家组. 儿童肝母细胞瘤诊疗规范(2019年版)[J]. 临床肝胆病杂志, 2019, 35( 11): 2431- 2434. DOI: 10.3969/j.issn.1001-5256.2019.11.008.
    [13]
    ZHEN ZJ, LIU JC, ZHOU L, et al. Treatment outcome of 100 patients with hepatoblastoma based on a new risk stratification[J]. Chin J Oncol, 2021, 43( 2): 228- 232. DOI: 10.3760/cma.j.cn112152-20190603-00347.

    甄子俊, 刘钧澄, 周李, 等. 100例肝母细胞瘤基于新危险分层的治疗结果分析[J]. 中华肿瘤杂志, 2021, 43( 2): 228- 232. DOI: 10.3760/cma.j.cn112152-20190603-00347.
    [14]
    MEYERS RL, MAIBACH R, HIYAMA E, et al. Risk-stratified staging in paediatric hepatoblastoma: A unified analysis from the Children’s hepatic tumors international collaboration[J]. Lancet Oncol, 2017, 18( 1): 122- 131. DOI: 10.1016/S1470-2045(16)30598-8.
    [15]
    HAFBERG E, BORINSTEIN SC, ALEXOPOULOS SP. Contemporary management of hepatoblastoma[J]. Curr Opin Organ Transplant, 2019, 24( 2): 113- 117. DOI: 10.1097/MOT.0000000000000618.
    [16]
    LIU J, DONG Q, XIU WL, et al. New progress of precision liver surgery in the treatment of children hepatoblastoma[J]. J Hepatopancreatobiliary Surg, 2024, 36( 12): 762- 768.

    刘洁, 董蒨, 修文丽, 等. 精准肝脏外科在儿童肝母细胞瘤治疗中的研究新进展[J]. 肝胆胰外科杂志, 2024, 36( 12): 762- 768.
    [17]
    KATZENSTEIN HM, LANGHAM MR, MALOGOLOWKIN MH, et al. Minimal adjuvant chemotherapy for children with hepatoblastoma resected at diagnosis(AHEP0731): A Children’s Oncology Group, multicentre, phase 3 trial[J]. Lancet Oncol, 2019, 20( 5): 719- 727. DOI: 10.1016/S1470-2045(18)30895-7.
    [18]
    ZSIROS J, BRUGIERES L, BROCK P, et al. Dose-dense cisplatin-based chemotherapy and surgery for children with high-risk hepatoblastoma(SIOPEL-4): A prospective, single-arm, feasibility study[J]. Lancet Oncol, 2013, 14( 9): 834- 842. DOI: 10.1016/S1470-2045(13)70272-9.
    [19]
    DEMBOWSKA-BAGIŃSKA B, WIĘCKOWSKA J, BROŻYNA A, et al. Health status in long-term survivors of hepatoblastoma[J]. Cancers, 2019, 11( 11): 1777. DOI: 10.3390/cancers11111777.
    [20]
    WU PV, RANGASWAMI A. Current approaches in hepatoblastoma-new biological insights to inform therapy[J]. Curr Oncol Rep, 2022, 24( 9): 1209- 1218. DOI: 10.1007/s11912-022-01230-2.
    [21]
    LIANG Y, GAO HX, SHAN YH, et al. Analysis of prognostic factors in children with hepatoblastoma[J]. Chin J Clin Med, 2022, 29( 3): 338- 345.

    梁煜, 高鸿翔, 单禹华, 等. 儿童肝母细胞瘤预后影响因素分析[J]. 中国临床医学, 2022, 29( 3): 338- 345.
    [22]
    LUPO PJ, SCHRAW JM, DESROSIERS TA, et al. Association between birth defects and cancer risk among children and adolescents in a population-based assessment of 10 million live births[J]. JAMA Oncol, 2019, 5( 8): 1150- 1158. DOI: 10.1001/jamaoncol.2019.1215.
    [23]
    HECK JE, MEYERS TJ, LOMBARDI C, et al. Case-control study of birth characteristics and the risk of hepatoblastoma[J]. Cancer Epidemiol, 2013, 37( 4): 390- 395. DOI: 10.1016/j.canep.2013.03.004.
    [24]
    ADAWY A, KOMOHARA Y, HIBI T. Tumor-associated macrophages: The key player in hepatoblastoma microenvironment and the promising therapeutic target[J]. Microbiol Immunol, 2024, 68( 8): 249- 253. DOI: 10.1111/1348-0421.13162.
    [25]
    BARROS JS, AGUIAR TFM, COSTA SS, et al. Copy number alterations in hepatoblastoma: Literature review and a Brazilian cohort analysis highlight new biological pathways[J]. Front Oncol, 2021, 11: 741526. DOI: 10.3389/fonc.2021.741526.
    [26]
    YU WY, LIU X, LI JQ, et al. A single-center retrospective analysis of childhood hepatoblastoma in China[J]. Gland Surg, 2020, 9( 5): 1502- 1512. DOI: 10.21037/gs-20-710.
    [27]
    YANG GJ, OUYANG HQ, ZHAO ZY, et al. Discrepancies in neglected tropical diseases burden estimates in China: Comparative study of real-world data and Global Burden of Disease 2021 data(2004-2020)[J]. BMJ, 2025, 388: e080969. DOI: 10.1136/bmj-2024-080969.
    [28]
    YUAN LN, TAO JX, WANG JC, et al. Global, regional, national burden of asthma from 1990 to 2021, with projections of incidence to 2050: A systematic analysis of the global burden of disease study 2021[J]. EClinicalMedicine, 2025, 80: 103051. DOI: 10.1016/j.eclinm.2024.103051.
    • Relative Articles
    • Supplements(0)
    • Cited By
  • 加载中

Catalog

    通讯作者: 陈斌, bchen63@163.com
    • 1. 

      沈阳化工大学材料科学与工程学院 沈阳 110142

    1. 本站搜索
    2. 百度学术搜索
    3. 万方数据库搜索
    4. CNKI搜索

    Figures(6)  / Tables(2)

    Get Citation
    PDF
    XML

    Article Metrics

    Article views (36) PDF downloads(12) Cited by()
    Proportional views
    Related
        

    The first journal specializing in hepatobiliary and pancreatic diseases in China

    Supervisor：Ministry of Education of the People's Republic of China

    Sponsor：Jilin University

    Academic Support: Chinese Society of Hepatology，Chinese Medical Association

    Address: 461 Xinjiang Road, Changchun

    Submit：0431-88782044

    Peer review：0431-88783542

    Email：lcgdb@vip.163.com

    About Journal

    Submission Guideline

    Journal Online

    Hepatobiliary College

    Guidelines

    YesterdayIP[]YesterdayPV[]TodayIP[]TodayPV[]Online[]

    Website Design © 2020 Editorial Board of Journal of Clinical Hepatology 吉ICP备10000617号-1 Supported by: Beijing Renhe Information Technology Co. Ltd  

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return